These results underscore the potential of TREX1 as a promising target for immunotherapeutic intervention and suggest that modulation of ICD and ferroptosis pathways may improve the precision of immunotherapy strategies in prostate cancer. This evidence concerns the gene TREX1 and Familial prostate cancer.